Vimta Labs Limited (VIMTALABS) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.180x

Based on the latest financial reports, Vimta Labs Limited (VIMTALABS) has a cash flow conversion efficiency ratio of 0.180x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs748.73 Million ≈ $8.10 Million USD) by net assets (Rs4.16 Billion ≈ $45.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VIMTALABS days of operational coverage to measure how many days the company can operate on defensive assets alone.

Vimta Labs Limited - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Vimta Labs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Vimta Labs Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vimta Labs Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Carlsmed, Inc. Common Stock
NASDAQ:CARL
-0.141x
Cosmo Electronics Corp
TW:2466
-0.020x
Ningbo United Group Co Ltd
SHG:600051
0.022x
Mosel Vitelic Inc
TW:2342
-0.011x
Papercorea
KO:001020
-0.054x
Leonteq AG
SW:LEON
0.774x
Evgo Inc
NASDAQ:EVGO
-0.100x
Aurion Resources Ltd
V:AU
-0.009x

Annual Cash Flow Conversion Efficiency for Vimta Labs Limited (2006–2025)

The table below shows the annual cash flow conversion efficiency of Vimta Labs Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Vimta Labs Limited.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs3.79 Billion
≈ $40.97 Million
Rs948.30 Million
≈ $10.26 Million
0.250x +31.42%
2024-03-31 Rs3.20 Billion
≈ $34.57 Million
Rs608.92 Million
≈ $6.59 Million
0.190x -38.97%
2023-03-31 Rs2.82 Billion
≈ $30.47 Million
Rs879.37 Million
≈ $9.51 Million
0.312x +23.62%
2022-03-31 Rs2.34 Billion
≈ $25.30 Million
Rs590.69 Million
≈ $6.39 Million
0.252x +31.98%
2021-03-31 Rs1.94 Billion
≈ $21.02 Million
Rs371.82 Million
≈ $4.02 Million
0.191x +35.82%
2020-03-31 Rs1.73 Billion
≈ $18.70 Million
Rs243.48 Million
≈ $2.63 Million
0.141x -38.28%
2019-03-31 Rs1.72 Billion
≈ $18.55 Million
Rs391.46 Million
≈ $4.23 Million
0.228x +4.81%
2018-03-31 Rs1.52 Billion
≈ $16.44 Million
Rs331.05 Million
≈ $3.58 Million
0.218x +23.92%
2017-03-31 Rs1.36 Billion
≈ $14.72 Million
Rs239.20 Million
≈ $2.59 Million
0.176x +2276.78%
2016-03-31 Rs1.26 Billion
≈ $13.64 Million
Rs-10.18 Million
≈ $-110.07K
-0.008x -106.45%
2015-03-31 Rs1.22 Billion
≈ $13.23 Million
Rs153.06 Million
≈ $1.66 Million
0.125x -10.34%
2014-03-31 Rs1.20 Billion
≈ $13.02 Million
Rs168.00 Million
≈ $1.82 Million
0.140x +1.10%
2013-03-31 Rs1.12 Billion
≈ $12.15 Million
Rs155.03 Million
≈ $1.68 Million
0.138x +16.97%
2012-03-31 Rs1.10 Billion
≈ $11.86 Million
Rs129.39 Million
≈ $1.40 Million
0.118x +77.91%
2011-03-31 Rs1.25 Billion
≈ $13.52 Million
Rs82.93 Million
≈ $896.82K
0.066x -64.58%
2010-03-31 Rs1.31 Billion
≈ $14.14 Million
Rs244.77 Million
≈ $2.65 Million
0.187x +1.40%
2009-03-31 Rs1.30 Billion
≈ $14.07 Million
Rs240.30 Million
≈ $2.60 Million
0.185x +83.97%
2008-03-31 Rs1.28 Billion
≈ $13.86 Million
Rs128.64 Million
≈ $1.39 Million
0.100x +418.23%
2007-03-31 Rs1.24 Billion
≈ $13.41 Million
Rs24.01 Million
≈ $259.70K
0.019x -88.04%
2006-03-31 Rs1.17 Billion
≈ $12.69 Million
Rs189.93 Million
≈ $2.05 Million
0.162x --

About Vimta Labs Limited

NSE:VIMTALABS India Diagnostics & Research
Market Cap
$273.75 Million
Rs25.31 Billion INR
Market Cap Rank
#15361 Global
#776 in India
Share Price
Rs567.10
Change (1 day)
+4.28%
52-Week Range
Rs380.70 - Rs877.20
All Time High
Rs1155.00
About

Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract researc… Read more